Jazz Pharma’s blood cancer therapy Rylaze wins US approval
Rylaze has been specifically developed for patients who have developed hypersensitivity to E.coli-derived asparaginase
Read More
Tag: acute lymphoblastic leukaemia
NICE evidence request for Blincyto for acute lymphoblastic leukaemia
NICE has requested further evidence on Amgen’s Blincyto for the treatment of adults with acute lymphoblastic leukaemia.
Read More
NICE issues final draft guidelines for Novartis’ Kymriah
NICE has recommended a pioneering cancer treatment for people under the age of 25 with leukaemia in final draft guidelines.
Read More
NICE nod for Amgen’s rare leukaemia drug
Patients with a rare form of leukaemia look set to win routine access to a novel treatment option on the NHS in England and Wales after Amgen’s Blincyto was backed by cost watchdog NICE.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
